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Attacking tumor cells with a dual ligand for innate immune 
receptors 
Johan Garaude and J. Magarian Blander
Nod-like receptors (NLRs) are being implicated in 
an increasing number of biological processes including 
carcinogenesis. Whether these innate immune receptors 
can be exploited in anti-tumor therapies is still uncertain. 
We have shown that engineered flagellin-bearing tumor 
cells trigger NLRs which cooperate with Toll-like receptor 
5 (TLR5) to induce robust anti-tumor T cell responses 
and tumor rejection. These findings demonstrate great 
potential for dual targeting of TLRs and NLRs in the 
design of optimal cancer vaccines. 
Pathogen-associated molecular patterns (PAMPs) are 
microbial structures that signify infection to the immune 
system upon engaging pattern recognition receptors 
(PRRs). Among PRRs, the NLRs constitute a recently 
identified family of cytosolic innate immune receptors 
that have been implicated in various diseases including 
cancer [1]. Some of these receptors have the ability to 
initiate the formation of multiprotein complexes, termed 
inflammasomes,  which  induce  caspase-1  activation  to 
mediate the proteolytic activation of the pro-inflammatory 
cytokines interleukin (IL)-1β and IL-18, and can initiate a 
programmed cell death termed pyroptosis. However, a first 
signal is needed to stimulate transcription of the precursors 
pro-IL-1β  and  pro-IL-18,  suggesting  that  some  NLRs 
can only function in co-operation with other signaling 
pathways  [1].  This  signal  can  efficiently  be  provided 
by engagement of another family of innate immune 
receptors, the Toll-like receptors (TLRs), activation of 
which leads to cytokine production, T cell co-stimulatory 
molecule expression, and enhanced antigen presentation 
[1,2]. While ligands for TLRs have been introduced as 
adjuvants in vaccine compositions and are currently being 
tested for use in the clinic, direct manipulation of NLR 
signaling has not been extensively explored. This will 
certainly change, however, especially with the recent 
demonstration that some clinically approved adjuvants 
rely on inflammasomes to mediate their actions [3].
Among NLR ligands, the bacterial protein flagellin 
is of particular interest since it is recognized by TLR5 
and the NLR NAIP5 (neuronal apoptosis inhibitor protein 
5), which partners with the NLR NLRC4 (NLR family, 
CARD domain containing protein 4) in the cytosol [4,5]. 
Therefore,  sensing  flagellin  by  myeloid  cells  such  as 
macrophages and dendritic cells (DCs) mobilizes signal 
transduction downstream of two major families of PRRs, a 
property that can possibly be exploited in immunotherapy. 
We tested this possibility by introducing flagellin into 
different tumor cell lines, a strategy that abrogated tumor 
development upon subcutaneous or intravenous injection 
of  these  flagellin-expressing  cells,  and  induced  DC-
mediated tumor antigen presentation to CD4+ and CD8+ 
T cells [6]. When used as a vaccine, irradiated flagellin-
bearing  tumor  cells  efficiently  protected  mice  from 
tumor development after challenge with parental tumor 
cell lines. Interestingly, mutation of specific leucines in 
the  C-terminal  domain  of  flagellin  abrogated  NAIP5/
NLRC4-mediated inflammasome formation [6,7], restored 
the ability of flagellin-expressing cells to form tumors in 
vivo, and impaired their anti-tumor vaccine properties. 
More surprisingly, we found that it also abrogated 
tumor-specific adaptive T cell responses, suggesting that 
NLR signaling was important for T cell priming [6]. In 
addition, abrogation of TLR5 signaling by use of TLR5 
deficient mice or the introduction of a mutation in the 
D1 domain of flagellin, also impaired immune responses 
demonstrating that flagellin recognition by TLR5 was also 
required [6]. Our results suggest that it can be possible 
to include adjuvants that directly target NLRs in future 
vaccine designs that already incorporate TLR stimulation. 
However, dual targeting of TLRs with NLRs will likely 
generate a particular cytokine environment that needs 
to be carefully assessed in the efforts to ameliorate the 
quality of anti-tumor immune responses.
Previous work by Blander and Medzhitov 
uncovered an interesting property of TLR signaling. 
Ensuring co-delivery of a TLR ligand with antigens into 
the same phagosome was superior in inducing major 
histocompatibility complex class II (MHC II)-mediated 
antigen  presentation  [8].  This  type  of  ‘associative 
recognition’ [2] of an antigen with PAMPs that engage 
TLRs could be exploited in tumor vaccine design. We 
thus hypothesized that tumor antigens would be favored 
for  presentation  to  T  cells  upon  introducing  flagellin 
into tumor cells. Indeed, we found that simply co-
injecting recombinant flagellin with tumor cells failed 
at  inducing  tumor  rejection  and  tumor-specific T  cell 
priming compared to engineering tumor cells to express 
flagellin [6]. Importantly, in a regimen of treating tumor-
bearing mice, co-injection of recombinant flagellin with 
irradiated tumor cells as a vaccine did not protect mice 
from subsequent challenge with parental tumor cells, and 
did not impair tumor progression. Our data can partially Oncotarget 2012; 3:  361-362 362 www.impactjournals.com/oncotarget
explain why some TLR ligands tested as single adjuvants 
in phase II and III clinical trials have failed at providing 
significant tumor regression [9].
Our findings indicate that at least two criteria must 
be met mounting a robust immune response against 
cancer cells: first, dual targeting of TLRs and NLRs with 
adjuvants, and second, ensuring their delivery with tumor 
cells to the same subcellular compartments within DC 
such that tumor antigens may be processed for optimal 
loading onto MHC molecules. These measures should 
hold paramount significance in the design of effective 
future cancer vaccines.
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